Skip to main content

Ulcerative Colitis Research Studies

Ulcerative colitis (UC) is an inflammatory bowel disease. It causes irritation, inflammation, and ulcers in the lining of the large intestine.

Investigators

5139-Bohm, Matthew

Matthew Bohm, BA, DO

Assistant Professor of Clinical Medicine

Read Bio

4964-Fischer, Monika

Monika Fischer, MD

Associate Professor of Medicine

Read Bio

5125-Sagi, Sashi

Sashi Sagi, MBBS

Assistant Professor of Clinical Medicine

Read Bio

Open Research Studies for Ulcerative Colitis

Seres Eco-Reset

Enrolling: Yes

Principle Investigator: Monika Fischer, MD

Duration: 17 Months (Approx. 7 clinic visits + two colonoscopies)

Patient Population:  Adult patients with mild to moderate Ulcerative Colitis

Study Intervention:  SER-287 Investigational Microbiome Drug

Possibility of Placebo:  1 in 3

Quasar

Enrolling: Will Begin Enrollment near the end of 2020

Principle Investigator: Sashidhar Sagi, MD

Duration: 15 months (with the option of an additional 2 years of treatment after)

Patient Population:  Adult patients with moderate to severe Ulcerative Colitis

Study Intervention:  Guselkumab

Possibility of Placebo: 1 in 3

SPARC IBD

Enrolling: On Hold

Principle Investigator:  Matthew Bohm, DO

Duration:  All bio-specimen collections and chart reviews will continue until 2026

Patient Population: Any patient with either Crohn’s Disease or Ulcerative Colitis

Study Intervention:  Medical chart reviews and biological specimen collection.

TOUR

Enrolling: Yes

Principle Investigator:  Monika Fischer, MD

Duration:  12 months

Patient Population: Any patient with Ulcerative Colitis starting Tofacitinib (Xeljanz) for the first time as part of their standard treatment for UC.

Study Intervention:  Medical chart review and e-mail patient questionnaires (Enrollment and participation is done via phone.)